MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: other"

  • 2024 International Congress

    Refining Aesthetic Eyebrows: Botulinum Toxin Injection for Hemifacial Spasm.

    S. Maytharakcheep, R. Bhidayasiri, O. Phokaewvarangkul (Bangkok, Thailand)

    Objective: To investigate the efficacy of botulinum toxin injection (BoNTA) in correcting eyebrow asymmetry in patients with hemifacial spasms (HFS). Background: HFS typically affects women…
  • 2024 International Congress

    Incobotulinumtoxin A to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 5-year Interim Results

    B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, G. Pollet, H. Couckuyt, L. Delameilleure, M. van Zandijcke (Bruges, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles (IC)). Background:…
  • 2024 International Congress

    Medication Refractory Restless Legs Syndrome: Real-World Experience

    P. Petramfar, J. Jankovic (Houston, USA)

    Objective: To identify demographic or clinical factors predictive of refractory cases. Background: Restless Legs Syndrome (RLS), impacting 5-13% of the US population, poses challenges in…
  • 2024 International Congress

    A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of OnabotulinumtoxinA for the Treatment of Upper Limb Essential Tremor: ELATE Trial

    K. Patterson, N. Alibhai, D. Khosla, L. James (North Chicago, USA)

    Objective: Here, we present the eligibility criteria and study design of ELATE, a Phase 2b clinical trial evaluating the safety and efficacy of onabotA compared…
  • 2024 International Congress

    Botulinum Toxin A Usage in Movement Disorder Division: A Retrospective Chart Review

    S. Shaikh, R. Figari Jordan (Charlottesville, USA)

    Objective: To evaluate the cost-effectiveness of Botulinum Toxin A in our movement disorder division. Background: Botulinum Toxin A is an FDA-approved treatment for various medical…
  • 2024 International Congress

    Real-World Retrospective Safety Analysis in Patients Treated With OnabotulinumtoxinA for Multiple Therapeutic Indications Over Repeat Treatment Periods

    G. Forde, A. Patel, K. Martinez, A. Mayadev, B. Brucker, T. Brown, Z. Ayyoub, R. Singh, M. Nelson, A. Ukah, I. Yushmanova, S. Battucci, K. Becker Ifantides, C. Rhyne (New Hyde Park, USA)

    Objective: To evaluate the real-world safety of onabotulinumtoxinA (onabotA) use over repeat treatment periods (TPs) in patients (pts) with concomitant multiple therapeutic indications. Background: In…
  • 2024 International Congress

    Predictors of Response to Botulinum Toxin Treatment in Patients With Hemifacial Spasm:A Prospective Study

    S. Jain, S. Pandey, RK. Garg, HS. Malhotra, I. Rizvi (Lucknow, India)

    Objective: To study the predictors of Good and Bad outcome and the impact on quality of life of patients with HFS following Botulinum toxin treatment.…
  • 2023 International Congress

    A randomised, double blind, placebo controlled, crossover trial of incobotulinum toxin A treatment for upper limb tremor

    S. Nagaratnam, D. Wilson, H. Morales Briceno, V. Fung (Westmead, Australia)

    Objective: To assess the clinical and functional outcomes in patients with upper limb tremor with incobotulinum toxin A injections. Background: Upper limb tremor can be…
  • 2023 International Congress

    Is a Parkinson’s Sialorrhoea service effective?

    C. Williams, J. Adenwalla, B. Mohamed, C. Marquis, C. Thomas, R. Lewis-Morton (cardiff, United Kingdom)

    Objective: Evaluate the efficacy and tolerance of Botulinum Toxin A (BoNT A) in managing sialorrhoea in People with Parkinsons (PwP)Assess impact on quality of life…
  • 2023 International Congress

    Botulinum neurotoxin in FXTAS-related tremor: a “successful” case report

    AT. Cimmino, P. Sanginario, AR. Bentivoglio, P. Calabresi, M. Petracca, G. Di Lazzaro (Rome, Italy)

    Objective: We report the case of a man affected by FXTAS, presenting with disabling tremor who experienced a significant and long-lasting benefit from botulinum neurotoxin…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 15
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley